Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ABHD11 | Q8NFV4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204157 | 0.81 | L3MBTL1 (0.41) | L3MBTL1POLBMAPTKCNH2HRH3 | |
| SCHEMBL9893038 | 0.79 | MEN1 (0.46) | CNR2L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL8520603 | 0.79 | CA2 (0.46) | L3MBTL1POLBMAPTKCNH2HRH3 | |
| SCHEMBL16480409 | 0.79 | CNR2 (0.44) | CNR2ALDH1A1 | |
| SCHEMBL28070422 | 0.76 | KMT2A (0.53) | L3MBTL1MAPTALDH1A1KDM4EDAGLA | |
| SCHEMBL9891849 | 0.75 | CNR2 (0.46) | CNR2KCNH2HRH3ALDH1A1 | |
| SCHEMBL9107274 | 0.74 | CNR2 (0.48) | CNR2 | |
| SCHEMBL16254904 | 0.74 | HPGD (0.46) | CNR2POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL10118444 | 0.72 | POLB (0.48) | L3MBTL1POLBMAPTALDH1A1KMT2A | |
| SCHEMBL2073337 | 0.72 | L3MBTL1 (0.48) | L3MBTL1POLBMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885L3MBTL1 4514/4885POLB 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.